nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

20.12.2023 | Original Article

Effects of medication on dopamine transporter imaging using [¹²³I]I-FP-CIT SPECT in routine practice

verfasst von: Yuliya Piatkova, Matthieu Doyen, Sébastien Heyer, Ayaz Tahmazov, Solene Frismand, Lucie Hopes, Laetitia Imbert, Antoine Verger

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dopamine transporter (DAT) imaging is used to support the diagnosis of neurodegenerative parkinsonian disorders. Specific medications have been reported to confound the interpretation of [¹²³I]I-FP-CIT SPECT scans, but there is limited data. The aim of the current study is to identify potential medication effects on the interpretation of [¹²³I]I-FP-CIT SPECT scans in routine practice.

Materials and methods

Consecutive patients undergoing a [¹²³I]I-FP-CIT SPECT/CT scan on a 360° CZT camera between September 2019 and December 2022 were included. An exhaustive review of patient medications (antidepressants, antipsychotics, anti-epileptics, anti-parkinsonians, benzodiazepines, lithium, opioids, and stimulants) was performed. Two experienced nuclear physicians, blinded to the medication reports, interpreted the [¹²³I]I-FP-CIT SPECT scans visually and a semi-quantitative analysis was performed using a local normal database.

Results

The study included 305 patients (71.0 ± 10.4, 135 women) and 145 (47.5%) visually interpreted normal scans. In normal scans, the striatum/occiput radioligand uptake ratio was decreased by noradrenergic and specific serotonergic antidepressants (NASSAs) (n = 15, z-score of − 0.93) and opioid medication (tramadol, n = 6, z-score of − 0.85) and was associated with a younger age in the multivariate analysis. In the overall population, the striatum/occiput ratio was influenced by NASSAs and associated with consensual visual analysis, age, sex, and anti-parkinsonian medications related to the status of the disease.

Conclusion

Our study confirms the potential impact of antidepressant (NASSA) and opioid (tramadol) medications on the semi-quantitative analysis of [¹²³I]I-FP-CIT SPECT scans. However, when performing a visual analysis, only NASSAs significantly impacted the interpretation of [¹²³I]I-FP-CIT SPECT scans.

Nur mit Berechtigung zugänglich

Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.PubMedPubMedCentralCrossRef

Verger A, Darcourt J, Habert M-O, Pallardy A, Santiago-Ribeiro M-J, Le Jeune F, et al. Guide de rédaction des protocoles d’examens d’imagerie de la neurotransmission pour l’exploration des mouvements anormaux. Médecine Nucl. 2021;45:98–111.CrossRef

Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging. 2023;50(7):1974-1987. https://doi.org/10.1007/s00259-023-06171-x.

Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424–38.PubMedCrossRef

Aster H-C, Romanos M, Walitza S, Gerlach M, Mühlberger A, Rizzo A, et al. Responsivity of the striatal dopamine system to methylphenidate—a within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder. Front Psychiatry. 2022;13: 804730.PubMedPubMedCentralCrossRef

Womack KB, Dubiel R, Callender L, Dunklin C, Dahdah M, Harris TS, et al. ¹²³ I-Iofluopane single-photon emission computed tomography as an imaging biomarker of pre-synaptic dopaminergic system after moderate-to-severe traumatic brain injury. J Neurotrauma. 2020;37:2113–9.PubMedCrossRef

Szobot CM, Shih MC, Schaefer T, Júnior N, Hoexter MQ, Fu YK, et al. Methylphenidate DAT binding in adolescents with attention-deficit/ hyperactivity disorder comorbid with substance use disorder - a single photon emission computed tomography with [Tc99m]TRODAT-1 study. Neuroimage. 2008;40:1195–201.PubMedCrossRef

Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148.PubMedPubMedCentralCrossRef

Borghammer P, Knudsen K, Danielsen E, Østergaard K. False-positive 123I-FP-CIT scintigraphy and suggested dopamine transporter upregulation due to chronic modafinil treatment. Clin Nucl Med. 2014;39:e87–8.PubMedCrossRef

10.

Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800–5.PubMedCrossRef

11.

Árgyelán M, Szabó Z, Kanyó B, Tanács A, Kovács Z, Janka Z, et al. Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005;89:115–23.PubMedCrossRef

12.

Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102–5.PubMedCrossRef

13.

Hsiao M-C, Lin K-J, Liu C-Y, Beck SD. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res Neuroimaging. 2013;211:72–7.CrossRef

14.

Honkanen EA, Kemppainen N, Noponen T, Seppänen M, Joutsa J, Kaasinen V. Bupropion causes misdiagnosis in brain dopamine transporter imaging for parkinsonism. Clin Neuropharmacol. 2019;42:181–3.PubMedPubMedCentralCrossRef

15.

Booij J, de Jong J, de Bruin K, Knol R, de Win MML, van Eck-Smit BLF. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359–66.PubMed

16.

Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2β-carbomethoxy-3β-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27:71–5.PubMedCrossRef

17.

Warwick JM, Carey PD, Cassimjee N, Lochner C, Hemmings S, Moolman-Smook H, et al. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis. 2012;27:151–8.PubMedCrossRef

18.

Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S, et al. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123I]β-CIT SPECT study. Eur Neuropsychopharmacol. 2015;25:873–81.PubMedCrossRef

19.

Wu C-K, Chin Chen K, See Chen P, Chiu N-T, Yeh TL, Lee IH, et al. No changes in striatal dopamine transporter in antidepressant-treated patients with major depression. Int Clin Psychopharmacol. 2013;28:141–4.PubMedCrossRef

20.

Krause D, Chrobok A, Karch S, Keeser D, Manz KM, Koch W, et al. Binding potential changes of SERT in patients with depression are associated with remission: a prospective [¹²³I]β-CIT-SPECT study. Exp Clin Psychopharmacol. 2023;31:219–27.PubMedCrossRef

21.

Schmitt GJE, Dresel S, Frodl T, la Fougère C, Boerner R, Hahn K, et al. Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2012;262:183–91.PubMedCrossRef

22.

Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology. 2007;191:805–11.PubMedCrossRef

23.

Lavalaye J, Linszen DH, Booij J, Dingemans PMAJ, Reneman L, Habraken JBA, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res. 2001;47:59–67.PubMedCrossRef

24.

Chang WH, Chen KC, Lee IH, Chi MH, Chen PS, Yao WJ, et al. Unaltered dopamine transporter availability in drug-naive patients with schizophrenia after 6 months of antipsychotics treatment: a naturalistic study. J Clin Psychopharmacol. 2017;37:21–6.PubMedCrossRef

25.

Hou H, Yin S, Jia S, Hu S, Sun T, Chen Q, et al. Decreased striatal dopamine transporters in codeine-containing cough syrup abusers. Drug Alcohol Depend. 2011;118:148–51.PubMedCrossRef

26.

Piatkova Y, Payoux P, Boursier C, Bordonne M, Roch V, Marie P-Y, et al. Prospective paired comparison of 123I-FP-CIT SPECT images obtained with a 360°-CZT and a conventional camera. Clin Nucl Med. 2022;47:14–20.PubMedCrossRef

27.

Lanfranchi F, Arnaldi D, Miceli A, Mattioli P, D’Amico F, Raffa S, et al. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB). Eur J Nucl Med Mol Imaging. 2023;50:1090–102.PubMedCrossRef

28.

Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014;17:343–54.PubMedCrossRef

29.

Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23:427–52.PubMedCrossRef

30.

de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10:19–23.PubMedCrossRef

31.

Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355:911–8.PubMedCrossRef

32.

Fasipe O. Neuropharmacological classification of antidepressant agents based on their mechanisms of action. Arch Med Health Sci. 2018;6:81.CrossRef

33.

Millan MJ, Gobert A, Rivet J-M, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α ₂ -adrenergic and serotonin _2C receptors: a comparison with citalopram: Monoamines and depression. Eur J Neurosci. 2000;12:1079–95.PubMedCrossRef

34.

Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands ¹²³ I-FP-CIT and ¹²³ I-PE2I. J Nucl Med. 2010;51:1885–91.PubMedCrossRef

35.

Justesen TEH, Borghammer P, Aanerud J, Hovind P, Marner L. Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism. EJNMMI Res. 2023;13:46.PubMedPubMedCentralCrossRef

36.

Chen F, Lawrence AJ. The effects of antidepressant treatment on serotonergic and dopaminergic systems in Fawn-Hooded rats: a quantitative autoradiography study. Brain Res. 2003;976:22–9.PubMedCrossRef

37.

Thibaut F, Bonnet J-J, Vaugeois J-M, Costentin J. Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice. Neurosci Lett. 1996;205:145–8.PubMedCrossRef

38.

Bergström KA, Jolkkonen J, Kuikka JT, Akerman KK, Viinamäki H, Airaksinen O, et al. Fentanyl decreases ?-CIT binding to the dopamine transporter. Synapse. 1998;29:413–5.PubMedCrossRef

39.

Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18:395–400.PubMed

40.

Hosseini-Sharifabad A, Rabbani M, Sharifzadeh M, Bagheri N. Acute and chronic tramadol administration impair spatial memory in rat. Res Pharm Sci. 2016;11:49–57.PubMedPubMedCentral

41.

Bameri B, Shaki F, Ahangar N, Ataee R, Samadi M, Mohammadi H. Evidence for the involvement of the dopaminergic system in seizure and oxidative damage induced by tramadol. Int J Toxicol. 2018;37:164–70.PubMedCrossRef

42.

Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6.PubMedCrossRef

43.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CIT. Mov Disord. 1999;14:436–42.PubMedCrossRef

44.

Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18 F]CFT PET study. J Cereb Blood Flow Metab. 2000;20:1604–9.PubMedCrossRef

45.

Winogrodzka A. [123I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:294–8.PubMedPubMedCentralCrossRef

46.

Fowler JS, Volkow ND, Logan J, Franceschi D, Wang G-J, MacGregor R, et al. Evidence that l-deprenyl treatment for one week does not inhibit mao a or the dopamine transporter in the human brain. Life Sci. 2001;68:2759–68.PubMedCrossRef

47.

Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559–64.PubMedCrossRef

48.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Parkinson study group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498–508. https://doi.org/10.1056/NEJMoa033447.

49.

Rossi C, Genovesi D, Marzullo P, Giorgetti A, Filidei E, Corsini GU, et al. Striatal dopamine transporter modulation after rotigotine: results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients. Clin Neuropharmacol. 2017;40:34–6.PubMedCrossRef

50.

Eusebio A, Azulay J-P, Ceccaldi M, Girard N, Mundler O, Guedj E. Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. Eur J Nucl Med Mol Imaging. 2012;39:1778–83.PubMedCrossRef

Titel: Effects of medication on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice
verfasst von: Yuliya Piatkova
Matthieu Doyen
Sébastien Heyer
Ayaz Tahmazov
Solene Frismand
Lucie Hopes
Laetitia Imbert
Antoine Verger
Publikationsdatum: 20.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06565-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effects of medication on dopamine transporter imaging using [¹²³I]I-FP-CIT SPECT in routine practice

Abstract

Purpose

Materials and methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Letter to the Editor: FDG Liver Biodistribution

Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance

Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer

[18F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica

First-in-human SPECT/CT imaging of [212Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor

Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy